Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.

[EN]Patients with schizophrenia and bipolar disorder have a life expectancy shorter than the general population. Cellular mechanisms underlying accelerated ageing, such as telomere shortening, may contribute to this premature mortality. We aimed to provide a comprehensive evaluation of the impact of...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez González, Juan Luis, Sánchez-Gil, Alba, Vicente-Muñoz, Elsa, Navarro López, Víctor, Martín Vallejo, Francisco Javier, Pérez, Jesús
Tipo de recurso: artículo
Estado:Versión borrador
Fecha de publicación:2025
País:España
Institución:Universidad de Salamanca (USAL)
Repositorio:GREDOS. Repositorio Institucional de la Universidad de Salamanca
OAI Identifier:oai:gredos.usal.es:10366/168284
Acceso en línea:http://hdl.handle.net/10366/168284
Access Level:acceso abierto
Palabra clave:Ageing
Antipsychotics
Bipolar disorder
Lithium
Meta-analysis
Schizophrenia
Telomere
Bipolar Disorder
Antipsychotic Agents
Humans
Telomere Shortening
humanos
acortamiento telomérico
antipsicóticos
trastorno bipolar
esquizofrenia
id ES_3c0441a928e2ff33497da76afb41b2a1
oai_identifier_str oai:gredos.usal.es:10366/168284
network_acronym_str ES
network_name_str España
repository_id_str
spelling Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.Sánchez González, Juan LuisSánchez-Gil, AlbaVicente-Muñoz, ElsaNavarro López, VíctorMartín Vallejo, Francisco JavierPérez, JesúsAgeingAntipsychoticsBipolar disorderLithiumMeta-analysisSchizophreniaTelomereBipolar DisorderSchizophreniaAntipsychotic AgentsHumansTelomere Shorteninghumanosacortamiento teloméricoantipsicóticostrastorno bipolaresquizofrenia[EN]Patients with schizophrenia and bipolar disorder have a life expectancy shorter than the general population. Cellular mechanisms underlying accelerated ageing, such as telomere shortening, may contribute to this premature mortality. We aimed to provide a comprehensive evaluation of the impact of pharmacological treatments for schizophrenia and bipolar disorder on telomere length. PRISMA/MOOSE systematic review and meta-analysis from inception to June 2024. PubMed, Cochrane Library, SCOPUS, Web of Science, Embase and PsycInfo databases were searched for eligible studies. Methodological quality and risk of bias were evaluated with the Newcastle-Ottawa Scale and the Risk of Bias In Non-randomized Studies - of Exposure (ROBINS-E) respectively. An initial search retrieved 2133 articles. However, only 28 studies were finally included in qualitative synthesis and 19 in meta-analysis. All studies identified in the review were observational. Random-effects model analysis was used to quantify the difference in telomere length between cohorts of patients with schizophrenia or bipolar disorder and healthy control groups. The meta-analysis confirmed that telomere length was shorter in patients with schizophrenia (SMD = 0.35, 95 % CI 0.11 to 0.60; p=<0.0001) and bipolar disorder (SMD = 0.18, 95 % CI -0.04 to 0.39 p=<0.0001) than in healthy controls. This difference was not modified by predominant treatment with either lithium (SMD = 0.37, 95 % CI 0.04 to 0.69; p=<0.0001) or antipsychotics (SMD = 0.20, 95 % CI 0.02 to 0.38; p=<0.0001) at cohort level across studies. Patients with schizophrenia or bipolar disorder have shorter telomeres than healthy populations. Predominant treatment with lithium or antipsychotics at cohort level did not have an impact on such shortening difference. PROSPERO CRD42024598840.Elsevier202520252025info:eu-repo/semantics/articleinfo:eu-repo/semantics/drafthttp://hdl.handle.net/10366/168284reponame:GREDOS. Repositorio Institucional de la Universidad de Salamancainstname:Universidad de Salamanca (USAL)InglésAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:gredos.usal.es:10366/1682842026-06-07T06:28:51Z
dc.title.none.fl_str_mv Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.
title Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.
spellingShingle Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.
Sánchez González, Juan Luis
Ageing
Antipsychotics
Bipolar disorder
Lithium
Meta-analysis
Schizophrenia
Telomere
Bipolar Disorder
Schizophrenia
Antipsychotic Agents
Humans
Telomere Shortening
humanos
acortamiento telomérico
antipsicóticos
trastorno bipolar
esquizofrenia
title_short Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.
title_full Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.
title_fullStr Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.
title_full_unstemmed Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.
title_sort Pharmacological interventions and telomere length in patients with schizophrenia and bipolar disorder: A systematic review and meta-analysis.
dc.creator.none.fl_str_mv Sánchez González, Juan Luis
Sánchez-Gil, Alba
Vicente-Muñoz, Elsa
Navarro López, Víctor
Martín Vallejo, Francisco Javier
Pérez, Jesús
author Sánchez González, Juan Luis
author_facet Sánchez González, Juan Luis
Sánchez-Gil, Alba
Vicente-Muñoz, Elsa
Navarro López, Víctor
Martín Vallejo, Francisco Javier
Pérez, Jesús
author_role author
author2 Sánchez-Gil, Alba
Vicente-Muñoz, Elsa
Navarro López, Víctor
Martín Vallejo, Francisco Javier
Pérez, Jesús
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Ageing
Antipsychotics
Bipolar disorder
Lithium
Meta-analysis
Schizophrenia
Telomere
Bipolar Disorder
Schizophrenia
Antipsychotic Agents
Humans
Telomere Shortening
humanos
acortamiento telomérico
antipsicóticos
trastorno bipolar
esquizofrenia
topic Ageing
Antipsychotics
Bipolar disorder
Lithium
Meta-analysis
Schizophrenia
Telomere
Bipolar Disorder
Schizophrenia
Antipsychotic Agents
Humans
Telomere Shortening
humanos
acortamiento telomérico
antipsicóticos
trastorno bipolar
esquizofrenia
description [EN]Patients with schizophrenia and bipolar disorder have a life expectancy shorter than the general population. Cellular mechanisms underlying accelerated ageing, such as telomere shortening, may contribute to this premature mortality. We aimed to provide a comprehensive evaluation of the impact of pharmacological treatments for schizophrenia and bipolar disorder on telomere length. PRISMA/MOOSE systematic review and meta-analysis from inception to June 2024. PubMed, Cochrane Library, SCOPUS, Web of Science, Embase and PsycInfo databases were searched for eligible studies. Methodological quality and risk of bias were evaluated with the Newcastle-Ottawa Scale and the Risk of Bias In Non-randomized Studies - of Exposure (ROBINS-E) respectively. An initial search retrieved 2133 articles. However, only 28 studies were finally included in qualitative synthesis and 19 in meta-analysis. All studies identified in the review were observational. Random-effects model analysis was used to quantify the difference in telomere length between cohorts of patients with schizophrenia or bipolar disorder and healthy control groups. The meta-analysis confirmed that telomere length was shorter in patients with schizophrenia (SMD = 0.35, 95 % CI 0.11 to 0.60; p=<0.0001) and bipolar disorder (SMD = 0.18, 95 % CI -0.04 to 0.39 p=<0.0001) than in healthy controls. This difference was not modified by predominant treatment with either lithium (SMD = 0.37, 95 % CI 0.04 to 0.69; p=<0.0001) or antipsychotics (SMD = 0.20, 95 % CI 0.02 to 0.38; p=<0.0001) at cohort level across studies. Patients with schizophrenia or bipolar disorder have shorter telomeres than healthy populations. Predominant treatment with lithium or antipsychotics at cohort level did not have an impact on such shortening difference. PROSPERO CRD42024598840.
publishDate 2025
dc.date.none.fl_str_mv 2025
2025
2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/draft
format article
status_str draft
dc.identifier.none.fl_str_mv http://hdl.handle.net/10366/168284
url http://hdl.handle.net/10366/168284
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:GREDOS. Repositorio Institucional de la Universidad de Salamanca
instname:Universidad de Salamanca (USAL)
instname_str Universidad de Salamanca (USAL)
reponame_str GREDOS. Repositorio Institucional de la Universidad de Salamanca
collection GREDOS. Repositorio Institucional de la Universidad de Salamanca
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869406342901399552
score 15.812429

Similares en LA Referencia